米氮平与氯米帕明治疗重性抑郁障碍的对照研究

目的：探讨米氮平治疗重性抑郁障碍的疗效和安全性。方法：将重性抑郁障碍诊断标准的72例门诊及住院患者随机分为两组,分别应用米氮平及氯米帕明治疗,疗程12周,在治疗前和治疗后1、2、4、8、12周分别使用汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）、临床疗效总评量表的病情严重程度（CGI–SI）、不良反应量表（TESS）评定疗效和不良反应。结果：两组有效率分别为81%和56%,前者起效更快,在疗效和不良反应方面两组均有显著差异（P〈0.05）。结论：米氮平治疗重性抑郁障碍疗效好,不良反应轻微,耐受性好。

Mirtazapine versus Clomipramine for Major Depressive Disorder

OBJECTIVE： To evaluate the clinical efficacy and safety of mirtazapine versus clomipramine in the treatment of major depressive disorder. METHODS： 72 patients with major depressive disorder were randomly assigned to receive either mirtazapine or clomipramine for 12 weeks. The clinical efficacy and safety were evaluated with HAMD,HAMA,CGI - SI and TESS at 0,1,2,4,8 and 12 weeks. RESULTS： The total response rate was 81% for mirtazapine - treated group versus 56% for clomipramine - treated group; however mirtazapine took effect more quickly. There were significant differences in clinical effects and side reactions between the two groups （ P〈0. 05）. CONCLUSION： Mirtazapine is effective,safe and well - tolerated for patients with major depressive disorders.